A pilot study evaluating multiple risk factor interventions by community pharmacists to prevent cardiovascular disease: The PAART CVD pilot project;Estudio piloto evaluando las intervenciones en pacientes con múltiples factores de riesgo realizadas por farmacéuticos de comunidad para prevenir enfermedad cardiovascular

Annals of Pharmacotherapy

Volumn 46, Issue 2, 2012, Pages 183-191

  McNamara, Kevin P ^a   O'Reilly, Sharleen L ^b   Dunbar, James A ^c   Bailey, Michael J ^a   George, Johnson ^a   Peterson, Gregory M ^d   Jackson, Shane L ^d   Janus, Edward D ^c,e   Bunker, Stephen ^c   Duncan, Gregory ^a   Howarth, Helen ^d  

^a MONASH UNIVERSITY   (Australia)

^b DEAKIN UNIVERSITY   (Australia)

^c Greater Green Triangle University Department of Rural Health   (Australia)

^d UNIVERSITY OF TASMANIA   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Cardiovascular disease; Community pharmacy

Indexed keywords

CARDIOVASCULAR AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DIETARY INTAKE; ETHNICITY; FAMILY HISTORY; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HEALTH BEHAVIOR; HUMAN; LIFESTYLE; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; OBESITY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHARMACIST; PHARMACY; PILOT STUDY; PRIORITY JOURNAL; RISK REDUCTION; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE;

AGED; CARDIOVASCULAR DISEASES; FEMALE; HEALTH BEHAVIOR; HUMANS; MALE; MIDDLE AGED; PHARMACIES; PHARMACISTS; PILOT PROJECTS; PRIMARY PREVENTION; PROFESSIONAL-PATIENT RELATIONS; PROGRAM EVALUATION; RISK FACTORS;

EID: 84857020342     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1Q572     Document Type: Article

References (41)

1. Lopez AD, Begg S, Bos E. Global burden of disease and risk factors. In: Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJL, eds. Demographic and epidemiological characteristics of major regions, 1990-2001. Oxford: Oxford University Press/World Bank, 2006.
2. Rose G. Sick individuals and sick populations. Int J Epidemiol 1985;14: 32-8. DOI 10.1093/ije/14.1.32
3. Vartiainen EA, Laatikainen T, Philpot B, Janus ED, Davis-Lameloise N, Dunbar JA. The projected impact of population and high-risk strategies for risk-factor control on coronary heart disease and stroke events. Med J Aust 2011;194:10-5.
4. Machado M, Bajcar J, Guzzo GC, Einarson TR. Sensitivity of patient outcomes to pharmacist interventions. Part I: systematic review and meta-analysis in diabetes management. Ann Pharmacother 2007;41: 1569-82. DOI 10.1345/aph.1K151
5. Clifford RM, Davis WA, Batty KT, Davis TME. Effect of a pharmaceutical care program on vascular risk factors in type 2 diabetes. Diabetes Care 2005;28:771-6. DOI 10.2337/diacare.28.4.771
6. Koshman SL, Charrois TL, Simpson SH, McAlister FA, Tsuyuki RT. Pharmacist care of patients with heart failure: a systematic review of randomized trials. Arch Intern Med 2008;168:687-94. DOI 10.1001/archinte.168.7.687
7. Krass I, Armour CL, Mitchell B, et al. The Pharmacy Diabetes Care Program: assessment of a community pharmacy diabetes service model in Australia. Diabet Med 2007;24:677-83. DOI 10.1111/j.1464-5491.2007.02143.x
8. Machado M, Bajcar J, Guzzo GC, Einarson TR. Sensitivity of patient outcomes to pharmacist interventions. Part II: systematic review and meta-analysis in hypertension management. Ann Pharmacother 2007; 41:1770-81. DOI 10.1345/aph.1K311
9. Machado M, Nassor N, Bajcar JM, Guzzo GC, Einarson TR. Sensitivity of patient outcomes to pharmacist interventions. Part III: systematic review and meta-analysis in hyperlipidemia management. Ann Pharmacother 2008;42:1195-207. DOI 10.1345/aph.1K618
10. Hourihan F, Krass I, Chen T. Rural community pharmacy: a feasible site for a health promotion and screening service for cardiovascular risk factors. Aust J Rural Health 2003;11:28-35. DOI 10.1046/j.1440-1584.2003.00468.x
11. Horgan JMP, Blenkinsopp A, McManus RJ. Evaluation of a cardiovascular disease opportunistic risk assessment pilot ("Heart MOT" service) in community pharmacies. J Public Health 2010;32:110-6. DOI 10.1093/pubmed/fdp092
12. National Vascular Disease Prevention Alliance. Guidelines for the assessment of absolute cardiovascular disease risk: National Heart Foundation of Australia. http://www.heartfoundation.org.au/Professional_Information/ General_Practice/Pages/AbsoluteRisk.aspx (accessed 2010 Apr 28).
13. Mosca L, Benjamin EJ, Berra K, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women-2011 update: a guideline from the American Heart Association. Circ 2011;123:1243-62. DOI 10.1161/CIR.0b013e31820faaf8
14. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J 2007;28:2375-414. DOI 10.1093/eurheartj/ehm316
15. World Health Organisation. Prevention of cardiovascular disease: guidelines for assessment and management of total cardiovascular risk. Geneva: WHO, 2007.
16. McNamara K, George J, O'Reilly S, et al. Engaging community pharmacists in the primary prevention of cardiovascular disease: protocol for the Pharmacist Assessment of Adherence, Risk and Treatment in Cardiovascular Disease (PAART CVD) pilot study. BMC Health Serv Res 2010; 10:264. DOI 10.1186/1472-6963-10-264
17. Schwarzer R. Modeling health behavior change: how to predict and modify the adoption and maintenance of health behaviors. Applied Psychology 2008;57:1-29. DOI 10.1111/j.1464-0597.2007.00325.x
18. Laatikainen T, Dunbar JA, Chapman A, et al. Prevention of type 2 diabetes by lifestyle intervention in an Australian primary health care setting: Greater Green Triangle (GGT) Diabetes Prevention Project. BMC Public Health 2007;7:249. DOI 10.1186/1471-2458-7-249
19. Absetz P, Valve R, Oldenburg B, et al. Type 2 diabetes prevention in the 'real world.' Diabetes Care 2007;30:2465-70. DOI 10.2337/dc07-0171
20. Tolonen H, Kuulasmaa K, Laatikainen T, Wolf H. European Health Risk Monitoring project. Recommendation for indicators, international collaboration, protocol and manual of operations for chronic disease risk factor surveys, 2002. http://www.ktl.fi/publications/ehrm/product2/title.htm (accessed 2007 May 16).
21. WHO MONICA Project Principal Investigators. The World Health Organization MONICA project (MONItoring trends and determinants in CArdiovascular disease): a major international collaboration. J Clin Epidemiol 1988;41:105-14. DOI 10.1016/0895-4356(88)90084-4
22. Greater Green Triangle University Department of Rural Health. Final project report: Greater Green Triangle Diabetes Prevention Project (GGT DPP). Warrnambool. http://www.greaterhealth.org/media/resources/Final_ DPP_Report_2006.pdf (accessed 2011 Sep 13).
23. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986; 24:67-74. DOI 10.1097/00005650-198601000-00007
24. George J, Mackinnon A, Kong DCM, Stewart K. Development and validation of the Beliefs and Behaviour Questionnaire (BBQ). Patient Educ Counsel 2006;64:50-60. DOI 10.1016/j.pec.2005.11.010
25. Kinect Australia for the Lifescripts consortium. Lifescripts practice manual: supporting lifestyle risk factor management in general practice. Canberra Commonwealth of Australia, 2005.
26. Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA, for the Ambulatory Care Quality Improvement Project. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Arch Intern Med 1998;158:1789-95. DOI 10.1001/archinte.158.16.1789
27. Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psych Meas 1977;1:385-401. DOI 10.1177/014662167700100306
28. Ware JE, Kosinski M, Turner-Bowker DM, Gandeck B. User's manual for the SF-12v2 Health Survey. Boston: Quality Metrics, 2007.
29. O'Reilly S, McCann L. Development and validation of the Diet Quality Tool for use in cardiovascular disease prevention settings. Australian Journal of Primary Care (published online). http://dx.doi.org/10.1071/ PY11005 (accessed 2011 Nov 18).
30. Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1991;121:293-8. DOI 10.1016/0002-8703(91)90861-B
31. Manuel DG, Lim J, Tanuseputro P, et al. Revisiting Rose: strategies for reducing coronary heart disease. BMJ 2006;332:659-62. DOI 10.1136/bmj.332.7542.659
32. Ebrahim S, Taylor F, Ward K, Beswick A, Burke M, Davey Smith G. Multiple risk factor interventions for primary prevention of coronary heart disease. Cochrane Database of Syst Rev 2011: Issue 1. Art. No. CD001561. DOI 10.1002/14651858.CD001561.pub3
33. Taveira TH, Wu W-C, Martin OJ, Schleinitz MD, Friedmann P, Sharma SC. Pharmacist-led cardiac risk reduction model. Prev Cardiol 2006; 9:202-8. DOI 10.1111/j.1520-037X.2006.05339.x
34. Liu Y, Mentele LJ, McDonough RP, Carruthers KM, Doucette WR. Community pharmacist assessment of 10-year risk of coronary heart disease for union workers and their dependents. J Am Pharm Assoc 2008; 48:515-7.
35. Mangum SA, Kraenow KR, Narducci WA. Identifying at-risk patients through community pharmacy-based hypertension and stroke prevention screening projects. J Am Pharm Assoc 2003;43:50-5. DOI 10.1331/JAPhA.2008.07099
36. Santsc V, Chiolero A, Burnand B, Colosimo AL, Paradis G. Impact of pharmacist care in the management of cardiovascular disease risk factors: a systematic review and meta-analysis of randomized trials. Arch Intern Med 2011;171:1441-53. DOI 10.1001/archinternmed.2011.399
37. Bunting B, Smith B, Sutherland S. The Asheville Project: clinical and economic outcomes of a community-based long-term medication therapy management program for hypertension and dyslipidemia. J Am Pharm Assoc 2008;48:23-31. DOI 10.1331/JAPhA.2008.07140
38. Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertens 2004;43:10-7. DOI 10.1161/01.HYP.0000103630.72812.10
39. Laatikainen T, Dunbar J, Chapman A, et al. Prevention of type 2 diabetes by lifestyle intervention in an Australian primary health care setting: Greater Green Triangle (GGT) Diabetes Prevention Project. BMC Public Health 2007;7:249. DOI 10.1186/1471-2458-7-249
40. Hebert JR, Clemow L, Pbert L, Ockene IS, Ockene JK. Social desirability bias in dietary self-report may compromise the validity of dietary intake measures. Int J Epidemiol 1995;24:389-98. DOI 10.1093/ije/24.2.389
41. Stein JH, Carlsson CM, Papcke-Benson K, Einerson JA, McBride PE, Wiebe DA. Inaccuracy of lipid measurements with the portable Cholestech LDX Analyzer in patients with hypercholesterolemia. Clin Chem 2002;48:284-90.